TEVA R&D Increase and Bristol Recruit Emphasize Biosimilars
This article was originally published in RPM Report
Executive Summary
The Obama Administration failed to clarify the biosimlar pathway for the start of 2012 with promised guidances, but the big players in biosimilars think they have a good fix on what the space will look like from a regulatory/development perspective. Take TEVA; the generic company’s actions and statements at the end of 2011 announce clearly that it sees a development-intensive, beyond-generic space developing in biosimilars.
You may also be interested in...
Believing In Biosimilars: Industry Takes Long View on FDA Pathway
FDA is open for business on biosimilars as it works out the specifics of the new review pathway. But for companies considering an entry into the space, two big questions still remain: Does a profitable market exist, and how conservative will FDA be on those initial approvals? Executives from across the biopharmaceutical industry weigh in during The RPM Report’s FDA/CMS Summit.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.